MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

MannKind Corporation

30930 Russell Ranch Road
Suite 301
Westlake Village, CA 91362
United States

Full Time Employees250

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael E. CastagnaCEO & Director378.41kN/A1977
Dr. David B. ThomsonGen. Counsel & Corp. Sec.458.68k424.8k1967
Mr. Steven B. BinderChief Financial OfficerN/AN/A1963
Mr. Joseph KocinskyChief Technology OfficerN/AN/A1964
Ms. Rosabel Realica AlinayaSr. VP of Investor Relations & TreasuryN/AN/A1961
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.